Abstract: A method and device for preferentially delivering a compound such as an antigen to the cytosol of an immune cell. The method comprises passing a cell suspension comprising the target immune cell through a microfluidic device and contacting the suspension with the compound(s) or payload to be delivered.
Type:
Grant
Filed:
October 30, 2015
Date of Patent:
September 7, 2021
Assignees:
Massachusetts Institute of Technology, President and Fellows of Harvard College
Inventors:
Armon R. Sharei, Shirley Mao, George Hartoularos, Sophia Liu, Megan Heimann, Pamela Basto, Gregory Szeto, Siddharth Jhunjhunwala, Darrell Irvine, Robert S. Langer, Klavs F. Jensen, Ulrich H. Von Andrian
Abstract: The present disclosure relates to a peripheral diagnostic method for screening Alzheimer's disease in patients based on quantitatively measured complexity of skin-sampled fibroblast networks.
Type:
Grant
Filed:
May 14, 2019
Date of Patent:
August 24, 2021
Inventors:
Florin V. Chirila, Tapan Kumar Khan, Daniel L. Alkon
Abstract: Methods and devices are disclosed for processing stromal precursor cells (i.e., cells which can differentiate into connective tissue cells, such as in muscles, ligaments, or tendons) which can be obtained from fatty tissue extracts obtained via liposuction. Normal processing of a liposuction extract involves centrifugation, to concentrate the stromal cells into a semi-concentrated form called “spun fat”. That “spun fat” can then be treated by mechanical processing (such as pressure-driven extrusion through 0.5 mm holes) under conditions which can gently pry the stromal cells away from extra-cellular collagen fibers and other debris in the “spun fat”. The extruded mixture is then centrifuged again, to separate a highly-enriched population of stromal cells which is suited for injection back into the patient (along with platelet cells, if desired, to further promote tissue repair or regeneration).
Abstract: This invention provides for a dry preserved formulation of Lactobacillus suitable for administration to people as a pro-biotic or live biotherapeutic treatment where the formulation is stable, has high potency, and contains no animal-derived excipients.
Abstract: Methods are described for identifying CDI patients as well as CDI patients at risk for recurrence. Embodiments include: (1) flow cytometry of circulating peripheral blood mononuclear cells (PBMC) to phenotype for the less efficient immunoglobulin response to bacterial toxins and surface antigens that characterizes patients who will become recurrent; (2) stratification by means of complete blood count (CBC) using a Coulter counter to detect the differences in lower angle light scatter (LAL), which has a larger range in the recurrent population; and (3) stratification by means of complete blood count (CBC) using a Coulter counter to detect the lower axial light loss (AL2) exhibited in recurrent patients.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
August 10, 2021
Assignee:
University of Cincinnati
Inventors:
Mary Elizabeth Yacyshyn, Bruce R. Yacyshyn, Julianne Qualtieri
Abstract: Methods and devices for detection of micro-organisms present or suspected to be present within a mammalian blood sample are provided. A selective lysis is obtained by incubating the sample in a non-ionic detergent under alkaline conditions.
Type:
Grant
Filed:
March 26, 2019
Date of Patent:
July 27, 2021
Assignee:
Koninklijke Philips N.V.
Inventors:
Bart Edward Gusta Jozef Van Meerbergen, Oana Mihaela Piciu, Ron Gill, Kristiane Anne Schmidt, Sieglinde Neerken, Marc Wilhelmus Gijsbert Ponjee, Zeynep Seflek Unay, Roel Penterman, Paul Arnold Van De Wiel
Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
Abstract: There is described an isolated 3-dimensional liver spheroid wherein said spheroid has: increased ATP content as compared to a 3-dimensional liver spheroid cultured in Complete William's E medium alone; the same or increased activity of cytochrome P450 1A1 and cytochrome P450 1B1 as compared to a 3-dimensional liver spheroid cultured in Complete William's E medium alone; and increased albumin secretion as compared to a 3-dimensional liver spheroid cultured in William's E medium alone.
Abstract: Disclosed are compositions of matter, cells, protocols and procedures useful for augmentation of one or more therapeutic activities of fibroblast cellular populations. In one embodiment fibroblasts are pretreated with growth factor-comprising composition(s), wherein the growth factor(s) may be cytokines, peptides, and/or proteins. In another embodiment fibroblasts are cultured with platelet rich plasma and/or derivatives from platelet rich plasma. In another embodiment, fibroblasts are cultured under hypoxic conditions prior to administration to an individual. The disclosure further provides means of assessment of fibroblast activity in vitro, including wound repair assay and cytokine production, for example.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
June 15, 2021
Assignee:
SpinalCyte, LLC
Inventors:
Pete O'Heeron, Thomas Ichim, Kristin Comella
Abstract: An apparatus for micromanipulation of biological material, includes a vessel (1) having a reservoir (2) wherein the vessel has a channel (3) formed in a portion of the reservoir, the channel including an intermediate restriction (4) dimensioned to resist passage of the biological material but allow passage of liquid treatment solutions.
Type:
Grant
Filed:
February 11, 2019
Date of Patent:
June 15, 2021
Assignee:
Genea IP Holdings Pty Limited
Inventors:
Chester John Henderson, Craig Matthew Lewis, Tammie Kim Roy, Eduardo Vom
Abstract: The present invention generally relates to a stem cell concentrate isolated from a mammalian vascularized adipose tissue, biopharmaceuticals containing such concentrate and use thereof in therapies for treating diseases in mammals.
Abstract: The present invention relates to a method of manufacturing a polycaprolactone nanostructure with improved cell adhesive ability containing fucoidan according to the present invention comprises dissolving fucoidan in glacial acetic acid as a solvent to obtain fucoidan-glacial acetic acid solution, mixing polycaprolactone with the fucoidan-glacial acetic acid solution to obtain a polycaprolactone-mixed solution, and manufacturing a nanostructure from the polycaprolactone-mixed solution by an electrospinning method. Therefore, a polycaprolactone nanostructure with improved cell adhesive ability containing fucoidan manufactured by the method according to the present invention exhibits characteristics of preventing fucoidan from being released from nanofibers by uniformly distributing fucoidan in the polycaprolactone nanostructure.
Type:
Grant
Filed:
March 12, 2019
Date of Patent:
April 6, 2021
Assignee:
AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Jong Young Kwak, Jung Min Kim, Yeo Jin Park, Dan Bi Park, Young Hun Jeong, Jeong Hwa Kim
Abstract: A molecular marker expressed specifically in corneal endothelial cells, and a method for producing one or more corneal endothelial cells using the marker and a method for evaluating one or more corneal endothelial cells using the marker are provided. At least one molecule selected from the group consisting of ZP4, MRGPRX3, GRIP1, GLP1R, HTR1D, and CLRN1 is used as a marker specific to corneal endothelial cells.
Abstract: A method of generating one of podocyte progenitor cells and neural stem/progenitor cells comprising the steps of collecting a urine specimen from a patient; centrifuging the urine specimen; and removing the one of podocyte progenitor cells and neural stem/progenitor cells.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
April 6, 2021
Assignee:
BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY
Abstract: The present invention provides an isolated lactic acid bacterium, Lactobacillus plantarum subsp. plantarum PS128 deposited under DSMZ Accession No. DSM 28632, for prophylaxis or treatment of a stress-induced disorder. The present invention further provides a composition for prophylaxis or treatment of a stress-induced disorder that comprises Lactobacillus plantarum subsp. plantarum PS128. Moreover, the present invention provides a method for prophylaxis or treatment of a stress-induced disorder in a subject that comprises a step of administering an effective amount of Lactobacillus plantarum subsp. plantarum PS128 to the subject.
Abstract: Described herein is a bone tissue clearing method with enhanced optical access. Compositions and techniques for bone tissue clearing include continuous convective flow during the clearing process, amino alcohol to minimize tissue autofluorescence, and an imaging procedure that minimizes refractive index variations in light-sheet microscopy. These improvements allowed the Inventors to achieve whole-bone clearing with an imaging depth of up to about 1.5 mm while maintaining fluorescence and a signal-to-noise ratio (SNR) that permits detection and 3D placement of single cells. In various embodiments, the present application teaches methods and kits for clearing and optionally subsequently visualizing tissue containing bone.
Type:
Grant
Filed:
January 18, 2018
Date of Patent:
March 23, 2021
Assignee:
California Institute of Technology
Inventors:
Viviana Gradinaru, Ken Y. Chan, Alon Grinbaum
Abstract: Disclosed is a method for quantifying HDL2 cholesterol in a test sample without requiring laborious operations. The method for quantifying cholesterol comprises allowing phospholipase to act on HDL to quantify cholesterol. Also disclosed is a method comprising: a first step of transferring cholesterols other than high-density lipoproteins in a test sample to the outside of the reaction system; and a second step of quantifying high-density lipoprotein 2 cholesterol among the high-density lipoproteins remaining in the reaction system; wherein, by performing the second step by the above method, high-density lipoprotein 2 cholesterol in the test sample can be quantified.
Abstract: The present invention is directed to topical compositions containing botulinum toxin, benzoyl peroxide, salicylic acid or a mixture of benzoyl peroxide and salicylic acid. The present invention is further directed to methods of treating acne or reducing rhytides with these topical compositions.